🇺🇸 aclacinomycin in United States

43 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Bone Marrow Failure — 12 reports (27.91%)
  2. Drug-Induced Liver Injury — 5 reports (11.63%)
  3. Haematotoxicity — 5 reports (11.63%)
  4. Infection — 5 reports (11.63%)
  5. Drug Ineffective — 4 reports (9.3%)
  6. Nausea — 3 reports (6.98%)
  7. Vomiting — 3 reports (6.98%)
  8. Blast Crisis In Myelogenous Leukaemia — 2 reports (4.65%)
  9. Lung Infection — 2 reports (4.65%)
  10. Off Label Use — 2 reports (4.65%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is aclacinomycin approved in United States?

aclacinomycin does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for aclacinomycin in United States?

Chinese PLA General Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.